Prime Medicine is sharpening its focus on key genetic therapy programs, including chronic granulomatous disease (CGD) and Wilson’s Disease. The company plans to deliver clinical data from its CGD Phase 1/2 trial in 2025, with an IND application for Wilson’s Disease expected by 2026.
A new partnership with Bristol Myers Squibb aims to develop multiple Prime Edited T-cell therapies, providing Prime Medicine with $110 million upfront. This collaboration, along with anticipated cost savings, is expected to extend the company’s cash runway into 2026, allowing for faster advancement of its pipeline.
Prime Medicine’s Prime Editing platform offers a promising approach to addressing genetic mutations. The company’s strategic focus on well-understood diseases and partnerships could accelerate the development of these one-time curative therapies, potentially transforming treatments for millions of patients worldwide.
Click here to read the original news story.